Yin D, Kondo S, Takeuchi J, Morimura T
Department of Neurosurgery, National Utano Hospital, Kyoto, Japan.
Oncol Res. 1993;5(9):383-7.
Bromocriptine, a dopamine agonist, is now an accepted primary therapeutic agent for patients with prolactinomas and other pituitary adenomas. In this study, we demonstrated that bromocriptine inhibited the proliferation of rat somatotrophin-secreting pituitary adenoma (GH1) cells. In addition, the antitumor activity of bromocriptine was inhibited both by actinomycin D and cycloheximide, suggesting that it was dependent upon new RNA and protein synthesis. Interestingly, the results of DNA fragmentation assay and cell cycle analysis clearly demonstrated that bromocriptine induced apoptosis in GH1 cells.
溴隐亭，一种多巴胺激动剂，现已成为催乳素瘤和其他垂体腺瘤患者公认的主要治疗药物。在本研究中，我们证明溴隐亭可抑制大鼠分泌生长激素的垂体腺瘤（GH1）细胞的增殖。此外，放线菌素D和环己酰亚胺均可抑制溴隐亭的抗肿瘤活性，这表明其作用依赖于新的RNA和蛋白质合成。有趣的是，DNA片段化分析和细胞周期分析结果清楚地表明，溴隐亭可诱导GH1细胞凋亡。
